

The 16th annual BIO Asia International Conference is an exclusive partnering forum that brings together the global biotechnology and pharmaceutical industry to explore licensing and research collaborations in the current Asia-Pacific business and policy environments. Gain insights into the changes, challenges, and opportunities key opinion and policy leaders foresee for the Japanese biotech market.

WHO SHOULD ATTEND:

- Drug development and discovery companies
- Biopharmaceutical companies
- Medical technology companies
- Universities and institutes
- Intellectual property and legal organizations
- Investors and financial services providers
- Bio-clusters and incubators
- Government and public support agencies

ATTENDANCE BY REGION




CO-HOSTED BY: **BioCentury**




SUPPORTED BY: U.S. Embassy Tokyo, Commercial Service
Japan External Trade Organization (JETRO)

COMPANY TYPES



PRIMARY THERAPEUTIC AREAS:

By Scheduled Meetings



HIGHLIGHTS / STATISTICS FROM PRIOR YEAR



440
DELEGATES



27
COUNTRIES



290+
COMPANIES
REPRESENTED



1,250+
BIO ONE-ON-ONE
PARTNERING MEETINGS



50
INNOVATIVE COMPANIES
FROM AROUND THE WORLD
PRESENTING THEIR STORY

EVENT ATTRIBUTES

- Opportunity for organizations to deliver company presentations, providing increased visibility in front of a global audience of biotech and pharmaceutical companies, all interested in cross-border business development alliances and research collaborations.
- BIO One-on-One Partnering enables attendees to: search company and investor profiles, drug assets, products, and services in the biopharma industry; evaluate potential collaborations and funding opportunities with participating companies; communicate directly with prospective investors and senior business and scientific management from the U.S., Japan, Europe, and the Asia Pacific region; and pre-schedule private, 30 minute One-on-One meetings to be conducted onsite.
- Panel discussions will increase your understanding of, and interaction with, the Japanese biotech market, the political landscape in Japan, and its impact on this important industry sector.
- Topics explored emerging deal-making trends, adapting clinical trial strategies across regulatory regimes, and shifts in Asian investment patterns among different therapeutic development specialties.
- Network with government leaders, peers, investors, and potential partners attending the conference and our exclusive welcome reception.
- The BIO SPARK Showcase is an excellent opportunity for academic researchers in the SPARK network to showcase drug development programs that are ready for partnering or venture funding. The conference is well attended by the business development units of major pharmaceutical companies, smaller specialty pharma/biotech companies looking to add to their pipelines, start-ups, and venture capital firms, an ideal venue for early-stage assets from the university setting.

PAST SPEAKERS



SEISHI BABA

Parliamentary Vice-Minister of Health, Labor and Welfare, Japan



SAMANTHA DU, PHD

Chairman, Chief Executive Officer, Zai Lab



PHILIPPE FAUCHET

OBE, President & Representative Director, GlaxoSmithKline K.K.



DAVID MEEKER, MD

Executive Vice President, Sanofi and Head of Sanofi Genzyme



JINGSONG WANG, MD, PHD

Chief Executive Officer, Harbour BioMed




SUBESH WILLIAMS

Senior Vice President, Global Corporate Development, GlaxoSmithKline plc

SPONSORSHIP OPPORTUNITIES

LOOKING TO INCREASE YOUR COMPANY'S VISIBILITY IN JAPAN?

Sponsorship Opportunities Include:

 Dedicated Partnering Suites	 Tabletops and Branding
 Program Sessions and Fireside Chats	 Networking & Hospitality

Benefits of sponsorship can include complimentary registrations, tabletop exhibit displays, speaking opportunities, and brand visibility.

For more information, please contact Adéla Wilson at sponsor@bio.org

REGISTRATION PACKAGES

Registration Categories

Investors
Discovery Company
Government / Academic / Non-Profit
Biotech / Pharma Company
Additional Attendee

Email register@bio.org for inquiries. For a full description of pricing categories or to register, visit our website at bio.org/asia

Apply to join the 2019 Committee by emailing your interest to nsagherian@bio.org.

2018 ADVISORY COMMITTEE

Kyle Hathaway, PhD

Director of Policy and Government Relations, Asia Pacific, MSD, Merck

Apo Huang, PhD

Secretary General, Taiwan Bio Industry Organization

Taro Inaba

Managing Partner, Remiges Ventures

Yuichi Iwaki, MD, PhD

President and Chief Executive Officer, MediciNova

Ryo Kubota, MD, PhD

Chairman, President, and Chief Executive Officer, Acucela

Bo Liu, PhD

Principal, Venture Investments, Johnson & Johnson Development Corporation – JJDC, Inc. (JJDC)

Arlene Morris

Chief Executive Officer, Willow Advisors

Kyle Murphy

Managing Director and Founder, KMG Japan

BT Slingsby, MD, PhD, MPH

Chief Executive Officer and Executive Director, Global Health Innovative Technology Fund

Charles Stacey, MD

Chief Executive Officer, Accera

Ted Tanaka

Partnering Consultant, Tanaka International LLC

Gil Van Bokkelen, PhD

Chairman and Chief Executive Officer, Athertsys